About CARE™
The CARE™ Faculty is recognizing its 15th year in 20/20 with education programming in a number of disease categories.
We develop education initiatives directed at our peers, nurses, pharmacists, patients, government and private payers.
LEARN MORE
Digital and/or Live Meetings & Publications
The COVID-19 outbreak requires that select meetings and education outputs be postponed/delayed.
With respect to upcoming meetings, digital meeting formats may be considered. Participating clinicians, allied health, government and supporting industry will be engaged to discuss interim options. We are grateful to all involved with keeping us safe and healthy. Education and information is always needed to make informed decisions. The various CARE™ faculty and staff continue to develop programming and outputs framed from a Canadian perspective.
[Recent] Publications
Hematology
Recap of the 3rd Annual:
CARE™ WHU 2020
Recap of this content-rich meeting that provided a forum for Ontario clinicians, trainees, and allied health care professionals to share the latest hematology news with an emphasis on ASH 2019.
View Publication
This comprised report includes presentation highlights from the National CARE™ Congress, along with forward-looking statements by CARE™ Faculty.
View Publication
Biosimilars
The 4th Annual:
CARE™ National Congress Report
Hematology
CARE™ Supplement:
Multiple Myeloma
The following CARE™ Supplement highlights key trial updates and data releases in the category of MM from the 2019 American Society of Hematology (ASH) annual meeting. This CARE™ Supplement focuses on daratumumab, one of the most impactful therapies on MM management in recent years.
View Publication
CARE™ at ASH happened on December 6th, 2019. CARE™ has provided a summary report and access to the speaker presentations.
View Publication
Hematology
CARE™ at ASH 2019:
Presentations & Report
Upcoming Reports
#DDW Report is online! Covering news and developments in UC and CD informed abstracts from #DDW2020. Dr. John Marshall, CARE™ Faculty reviews treatment options and considers impact within the context of Canadian #healthcare https://careeducation.ca/reports/care-perspectives-ddw-report/ @marshllj
Effects of a high-dose 24-h infusion of tranexamic acid on death and thromboembolic events in patients with acute gastrointestinal bleeding (HALT-IT): an international randomised, double-blind, placebo-controlled trial https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30848-5/fulltext#.XvOq3pN50CM.twitter
